Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Attention Deficit Study In Healthy Children Can Proceed Under Certain Conditions, Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH proposal to administer dextroamphetamine to healthy children represents only a slightly greater than minimal risk to study participants, FDA's Pediatric Ethics Subcommittee says. The Pediatric Advisory Committee will review the recommendations Sept. 15.

You may also be interested in...



Dextroamphetamine Study Should Avoid Prior Stimulant Use, Pediatric Cmte. Says

FDA committee accepts recommendation from its Pediatric Ethics Subcommittee to allow a study of dextroamphetamine in healthy children to proceed. Stimulants should not be provided to participants prior to enrollment, committee says.

Dextroamphetamine Study Should Avoid Prior Stimulant Use, Pediatric Cmte. Says

FDA committee accepts recommendation from its Pediatric Ethics Subcommittee to allow a study of dextroamphetamine in healthy children to proceed. Stimulants should not be provided to participants prior to enrollment, committee says.

Dextroamphetamine Study Including Healthy Children Will Be First Test For Pediatric Ethics Subcommittee

NIH study proposes single-dose administration to both children with attention deficit/hyperactivity disorder and healthy volunteers. Institutional Review Board requested special review from HHS after two divided votes.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel